159938 医药
已收盘 07-31 15:00:00
资讯
新帖
简况
股市必读：白云山新发布《关于兴业圆融-广州医药应收账款4期资产支持专项计划清算的公告》
证券之星 · 34分钟前
股市必读：白云山新发布《关于兴业圆融-广州医药应收账款4期资产支持专项计划清算的公告》
每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议
证券之星 · 08-02 03:17
每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议
7月31日益方生物跌5.13%，汇添富创新医药混合A基金重仓该股
证券之星 · 07-31 16:39
7月31日益方生物跌5.13%，汇添富创新医药混合A基金重仓该股
被AI“做空”的印度股市迎来修复行情：IT股强势反弹 银行、电力、医药板块受青睐
中金财经 · 07-31 14:07
被AI“做空”的印度股市迎来修复行情：IT股强势反弹 银行、电力、医药板块受青睐
新济医药二次递表港交所：竞品林立临床价值待验证 家族治理隐忧浮现
新浪证券 · 07-31 14:05
新济医药二次递表港交所：竞品林立临床价值待验证 家族治理隐忧浮现
被AI“做空”的印度股市迎来修复行情：IT股强势反弹 银行、电力、医药板块受青睐
智通财经 · 07-31 13:30
被AI“做空”的印度股市迎来修复行情：IT股强势反弹 银行、电力、医药板块受青睐
新股前瞻 | 亦诺微医药：临床进展提速，但18A创新药的资金考验仍在
智通财经 · 07-31 10:21
新股前瞻 | 亦诺微医药：临床进展提速，但18A创新药的资金考验仍在
医药外包概念整体回暖 昭衍新药（06127）涨4.51%、康龙化成（03759）涨3.10%
金吾财讯 · 07-31 10:18
医药外包概念整体回暖 昭衍新药（06127）涨4.51%、康龙化成（03759）涨3.10%
华人健康：公司管理层始终立足长期经营，持续看好医药主业长远发展
证券之星 · 07-31 08:27
华人健康：公司管理层始终立足长期经营，持续看好医药主业长远发展
股市必读：新发布《迪哲医药：北京市中伦律师事务所关于迪哲（江苏）医药股份有限公司2026年第二次临时股东会的法律意见书》
证券之星 · 07-31
股市必读：新发布《迪哲医药：北京市中伦律师事务所关于迪哲（江苏）医药股份有限公司2026年第二次临时股东会的法律意见书》
迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%
证券之星 · 07-30
迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%
7月30日热景生物跌6.70%，富国医药创新股票A基金重仓该股
证券之星 · 07-30
7月30日热景生物跌6.70%，富国医药创新股票A基金重仓该股
昌郁医药完成2.5亿元D轮融资；国内首个长效胰岛素类似物获批上市 ｜医药早参
每日经济新闻 · 07-30
昌郁医药完成2.5亿元D轮融资；国内首个长效胰岛素类似物获批上市 ｜医药早参
国泰海通｜医药：医药行业2026Q2公募基金持仓分析
国泰君安证券研究 · 07-29
国泰海通｜医药：医药行业2026Q2公募基金持仓分析
我国上半年医药流通行业市场规模约1.54万亿元 同比增长约4%
格隆汇 · 07-29
我国上半年医药流通行业市场规模约1.54万亿元 同比增长约4%
3.3亿元控股法玛星医药， 广药集团产业并购再进一步
新京报 · 07-29
3.3亿元控股法玛星医药， 广药集团产业并购再进一步
礼邦医药-B(09637)因超额配股权获行使而发行851.33万股
智通财经 · 07-29
礼邦医药-B(09637)因超额配股权获行使而发行851.33万股
解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选
每日经济新闻 · 07-29
解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选
华宝医药精选混合拟发行 2基金经理共3产品回报亏超1成
中金财经 · 07-29
华宝医药精选混合拟发行 2基金经理共3产品回报亏超1成
新济医药冲击IPO，报告期内累计亏损4.55亿元，家族色彩浓厚
格隆汇 · 07-29
新济医药冲击IPO，报告期内累计亏损4.55亿元，家族色彩浓厚
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.645,"timestamp":1785481380000,"preClose":0.638,"halted":0,"volume":59042000,"delay":0,"changeRate":0.011,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0.007,"latestTime":"07-31 15:00:00","open":0.637,"high":0.646,"low":0.633,"amount":37965100,"amplitude":0.0204,"askPrice":0.645,"askSize":1824,"bidPrice":0.644,"bidSize":862,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785720600000},"marketStatusCode":5,"adr":0,"adjPreClose":0.638,"symbolType":"fund","openAndCloseTimeList":[[1785461400000,1785468600000],[1785474000000,1785481200000]],"highLimit":0.702,"lowLimit":0.574,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.392939,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938","defaultTab":"news","newsList":[{"id":"2656985348","title":"股市必读：白云山新发布《关于兴业圆融-广州医药应收账款4期资产支持专项计划清算的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656985348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656985348?lang=zh_cn&edition=full","pubTime":"2026-08-03 01:05","pubTimestamp":1785690311,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，白云山报收于22.28元，上涨0.36%，换手率0.86%，成交量12.1万手，成交额2.67亿元。当日关注点交易信息汇总：7月31日主力资金净流入2014.43万元，占总成交额7.54%。公司公告汇总：兴业圆融-广州医药应收账款4期资产支持专项计划已于2026年7月17日清算完毕，专项计划账户余额为0.00元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0028","09939","BK0012","BK0097","BK0183","BK0175","600332","BK1521","BK1574","BK0239","BK0096","159938","BK0196","BK1197","BK0188","BK1606","BK1161","BK0070","BK1191","00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656196943","title":"每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2656196943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656196943?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:17","pubTimestamp":1785611830,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，迪哲医药报收于51.05元，较上周的55.6元下跌8.18%。本周，迪哲医药7月27日盘中最高价报57.3元。本周关注点公司公告汇总：迪哲医药股东大会通过与阿斯利康签署授权许可协议的议案，获99.9536%同意票。议案获普通股股东同意票186,456,608股，占比99.9536%，中小投资者同意比例为99.4234%。北京市中伦律师事务所出具法律意见书，确认会议召集、召开程序及表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK1515","BK1161","BK0239","688192","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655381359","title":"7月31日益方生物跌5.13%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655381359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655381359?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:39","pubTimestamp":1785487152,"startTime":"0","endTime":"0","summary":"证券之星消息，7月31日益方生物跌5.13%，收盘报20.16元，换手率4.33%，成交量25.12万手，成交额5.21亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为89.62亿元，最新净值1.6878，较上一交易日下跌2.93%，近一年下跌15.35%。汇添富创新医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100027432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1161","BK1515","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655723332","title":"被AI“做空”的印度股市迎来修复行情：IT股强势反弹 银行、电力、医药板块受青睐","url":"https://stock-news.laohu8.com/highlight/detail?id=2655723332","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655723332?lang=zh_cn&edition=full","pubTime":"2026-07-31 14:07","pubTimestamp":1785478022,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在全球AI交易剧烈震荡的背景下，印度股市反弹，Nifty IT指数在7月强势上涨近19%。印度第二大资产管理公司ICICI Prudential Asset Management 押注银行、炼油、电力、制药板块，看好需求端带来的投资机遇。纳伦表示，银行业估值具备吸引力，此外，电力基建、医疗领域需求攀升也带来了极具吸引力的投资机会。 “银行业仍然是印度最具吸引力的行业之一，”他在周三接受采访时表示。此外，外资流入回升以及印度软件股反弹也提振了市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260731/32322807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["SMIN","PEMX","VEU","BCHI","DEXC","EEMA","VTHR","159938","INDZ","EEMV","FEMR","AVEM","09939","MEMX","QLVE","AEF","XCEM","NFTY","TEMR","SPEM","STXE","PIN","INQQ","DFAE","SCHE","ASIA","INDH","SCIN","EQLT","TEMX","XSOE","HEEM","BKF","XC","CHAT","VGT","BKEM","EMXC","IMVP","159146","RWEM","SEEM","FLIN","ARTY","EET","TAJX","QTOC","RAYE","VEXC","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655477332","title":"新济医药二次递表港交所：竞品林立临床价值待验证 家族治理隐忧浮现","url":"https://stock-news.laohu8.com/highlight/detail?id=2655477332","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655477332?lang=zh_cn&edition=full","pubTime":"2026-07-31 14:05","pubTimestamp":1785477900,"startTime":"0","endTime":"0","summary":"近日，广州新济医药股份有限公司第二次向港交所递交招股书，拟以18A章规则登陆港股主板。新济医药主打可溶性微针与鼻腔吸入两大制剂技术平台，核心产品均处于临床II期阶段，尚未有任何产品实现商业化。其中，DHMP是新济医药最受关注的产品，定位为儿童及成人术前镇静，也是目前国内唯一进入II期临床的可溶性微针药物贴剂。股权结构上，新济医药呈现出高度集中的家族控制特征。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-07-31/doc-iniksnxi0959328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1161","IPOS","BK1574","HEXmain","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655211334","title":"被AI“做空”的印度股市迎来修复行情：IT股强势反弹 银行、电力、医药板块受青睐","url":"https://stock-news.laohu8.com/highlight/detail?id=2655211334","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655211334?lang=zh_cn&edition=full","pubTime":"2026-07-31 13:30","pubTimestamp":1785475810,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在全球AI交易剧烈震荡的背景下，印度股市反弹，Nifty IT指数在7月强势上涨近19%。此前市场担忧AI技术将颠覆印度IT外包产业的商业模式，印度科技板块遭遇深度调整。市场甚至出现论调，称印度是首个被AI“做空”的国家，悲观情绪蔓延至资本市场与长期经济前景。不过，随着AI芯片股近期回调，资金开始轮动布局印度IT服务板块，将其视作风险相对更低的科技赛道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AVEM","RAYE","EEMA","159938","INDH","MEMX","INQQ","PIN","EEMV","INDE","XCNY","BCHI","PEMX","XCEM","SCHE","VGT","FEMR","AEF","MFEM","EPI","BKF","ARTY","INDQ","QLVE","SPEM","VTHR","TEMR","EMES","SEEM","RWEM","AGIX","FLIBF","SMIN","EQLT","IOPP","QTOC","XC","XSOE","INDY","NFTY","INDZ","STXE","BBEM","HEEM","IND","CHAT","FLIN","EET","BKEM","IMVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655333213","title":"新股前瞻 | 亦诺微医药：临床进展提速，但18A创新药的资金考验仍在","url":"https://stock-news.laohu8.com/highlight/detail?id=2655333213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655333213?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:21","pubTimestamp":1785464470,"startTime":"0","endTime":"0","summary":"从招股书披露的数据来看，亦诺微近年来整体经营特征符合港股18A创新药企业普遍规律，即持续保持较高研发投入、经营现金流持续净流出，同时依赖股权融资和合作授权维持研发推进。收入结构方面，亦诺微目前尚未形成稳定产品销售收入，整体收入仍主要来自合作授权及其他经营收入，因此收入规模波动较大。整体来看，亦诺微当前仍是一家典型的研发型创新药企业，其价值更多建立在未来而非当下。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","IBBQ","BK1515","159938","BK1574","MEDX","BK1161","LNGR","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655333030","title":"医药外包概念整体回暖 昭衍新药（06127）涨4.51%、康龙化成（03759）涨3.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655333030","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655333030?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:18","pubTimestamp":1785464310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念整体回暖，截止发稿，昭衍新药 涨4.51%，康龙化成涨3.10%，金斯瑞生物科技涨2.97%，凯莱英涨2.77%，药明生物涨2.75%，药明康德涨2.60%，泰格医药涨1.39%。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987205","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","LU0516423091.SGD","LU1242518931.SGD","LU3063872942.SGD","LU0823426480.USD","02269","LU0140636845.USD","603127","06821","159938","LU0417516738.SGD","LU0359201612.USD","03347","LU0588546209.SGD","LU0823426308.USD","BK1191","BK1589","BK1521","SG9999002463.SGD","03759","HK0000306701.USD","LU2045819591.USD","LU0348735423.USD","LU1880383366.USD","300759","LU0456827905.SGD","LU0708995583.HKD","01548","LU0348766576.USD","LU0348825331.USD","LU1794554557.SGD","LU0307460666.USD","BK1574","LU0051755006.USD","06127","02359","LU0359202008.SGD","LU0516422366.SGD","LU0819121731.USD","09939","BK1141","LU1046422090.SGD","HK0000306685.HKD","LU1242518857.USD","LU0327786744.USD","LU0516422440.USD","LU1720050803.USD","KURE","LU0320764599.SGD","LU0181495838.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655387798","title":"华人健康：公司管理层始终立足长期经营，持续看好医药主业长远发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2655387798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655387798?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:27","pubTimestamp":1785457629,"startTime":"0","endTime":"0","summary":"贵公司股票股价已经跌破发行价，并且，相对于2026年1月14日的高点收盘价29.66元，目前价格在13.80元，已经跌了53%，已经腰斩！请问，贵公司懂事们是否还继续看好公司的发展？公司管理层、董事会成员始终立足长期经营，持续看好医药主业长远发展，专注推进药品研发、产品落地、市场拓展、精细化运营等核心经营工作，扎实夯实公司基本面，以稳定可持续的经营成果回馈全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100006942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1161","301408","BK1515","09939","BK0209","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655802400","title":"股市必读：新发布《迪哲医药：北京市中伦律师事务所关于迪哲（江苏）医药股份有限公司2026年第二次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655802400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655802400?lang=zh_cn&edition=full","pubTime":"2026-07-31 01:16","pubTimestamp":1785431805,"startTime":"0","endTime":"0","summary":"表决结果显示，该议案获得出席会议股东所持有效表决权股份的99.9536%同意，表决结果合法有效。迪哲医药：2026年第二次临时股东会决议公告迪哲（江苏）医药股份有限公司于2026年7月30日召开2026年第二次临时股东会，审议通过《关于与阿斯利康签署授权许可协议暨关联交易的议案》。北京市中伦律师事务所对本次会议出具法律意见书，认为会议召集、召开程序及表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","09939","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655805121","title":"迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655805121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655805121?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:17","pubTimestamp":1785421034,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，迪哲医药报收于51.16元，较前一交易日下跌4.07%，最新总市值为237.98亿元。近日，迪哲（江苏）医药股份有限公司召开2026年第二次临时股东会，审议通过《关于与阿斯利康签署授权许可协议暨关联交易的议案》。会议于2026年7月30日以现场和网络投票方式召开，出席会议股东188人，代表表决权40.1024%。议案获普通股股东同意票186,456,608股，占比99.9536%，中小投资者对该议案同意比例为99.4234%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","159938","BK1161","BK0239","BK1515","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655243048","title":"7月30日热景生物跌6.70%，富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655243048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655243048?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:37","pubTimestamp":1785400662,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日热景生物跌6.70%，收盘报103.11元，换手率3.83%，成交量3.55万手，成交额3.81亿元。重仓热景生物的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，增持评级2家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000025884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","688068","BK0239","159938","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655810219","title":"昌郁医药完成2.5亿元D轮融资；国内首个长效胰岛素类似物获批上市 ｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2655810219","media":"每日经济新闻","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655810219?lang=zh_cn&edition=full","pubTime":"2026-07-30 07:03","pubTimestamp":1785366194,"startTime":"0","endTime":"0","summary":"丨2026年7月30日星期四丨NO.1亚太药业：拟1000万元至2000万元回购股份亚太药业公告，公司拟1000万元（含）至2000万元（含）回购股份，用于实施股权激励或者员工持股计划，回购价格不超过7元/股（含）。点评：本次回购规模不大，上限2000万元，回购股份用于员工激励，意在绑定核心团队；叠加公司上半年主业扣非扭亏，传递管理层经营改善信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303825563428.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303825563428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1161","IPOS","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655890674","title":"国泰海通｜医药：医药行业2026Q2公募基金持仓分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2655890674","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655890674?lang=zh_cn&edition=full","pubTime":"2026-07-29 21:58","pubTimestamp":1785333480,"startTime":"0","endTime":"0","summary":"从整体看，2026Q2全部基金医药股持仓占比下降。截至2026Q2，全部公募基金重仓持股中，医药股持仓比为6.54%，较2026Q1下降2.33pp；医药公募基金重仓持股中，医药股持仓比为96.24%，较2026Q1上升0.21pp；非医药公募基金重仓持股中，医药股持仓比为3.20%，较2026Q1下降1.67pp。2026Q2公募基金重仓持股市值前五名：药明康德、恒瑞医药、信达生物、百济神州、凯莱英。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650540075&idx=7&sn=5bd8de4f92f7ce95dd4a932636e607e3&chksm=89bbb2eb6c3f345a2aed0e4d29823ef519393bfbed6185cd01f125157e43dccdc10f06a85e76&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK0184","BK0276","601211","BK1161","BK0183","BK1564","BK1515","BK1574","02611","BK0028","159938","BK0012","BK0188","09939","BK1147","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655981588","title":"我国上半年医药流通行业市场规模约1.54万亿元 同比增长约4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655981588","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655981588?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:43","pubTimestamp":1785329034,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159938","BK1515","09939","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655867780","title":"3.3亿元控股法玛星医药， 广药集团产业并购再进一步","url":"https://stock-news.laohu8.com/highlight/detail?id=2655867780","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655867780?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:42","pubTimestamp":1785325320,"startTime":"0","endTime":"0","summary":"广药集团的并购布局再进一步。本周，广药集团旗下广州白云山何济公药业有限公司（以下简称白云山何济公）以3.3亿元的交易对价，收购北京法玛星医药科技有限公司（以下简称法玛星医药）股权并成为其控股股东。广药集团也凭借此举进军新型透皮贴剂领域。广药集团“十五五”时期计划投入300亿元用于产业并购与管线合作。从已有动作来看，广药集团收购已涉及医药流通、中药、分子诊断等多领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825260517.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825260517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KCE","09939","BK1515","159938","CALF","MYLD","BK4585","XMMO","BK1161","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655863629","title":"礼邦医药-B(09637)因超额配股权获行使而发行851.33万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655863629","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655863629?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:23","pubTimestamp":1785317006,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B(09637)发布公告，于2026年7月29日根据悉数行使超额配股权而发行及配发的H股股份851.33万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","09637","BK1515","159938","BK1574","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860463","title":"解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860463","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655860463?lang=zh_cn&edition=full","pubTime":"2026-07-29 16:44","pubTimestamp":1785314640,"startTime":"0","endTime":"0","summary":"7月28日，2026年《财富》世界500强榜单正式发布。《每日经济新闻》记者（以下简称每经记者）注意到，医疗健康板块作为全球五大支柱行业之一，共有31家企业上榜。其中，礼来公司排名从2025年 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://field.10jqka.com.cn/20260729/c678521179.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://field.10jqka.com.cn/20260729/c678521179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655850141","title":"华宝医药精选混合拟发行 2基金经理共3产品回报亏超1成","url":"https://stock-news.laohu8.com/highlight/detail?id=2655850141","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655850141?lang=zh_cn&edition=full","pubTime":"2026-07-29 16:29","pubTimestamp":1785313741,"startTime":"0","endTime":"0","summary":"中国经济网北京7月29日讯 今日，华宝基金管理有限公司发布华宝医药精选混合型证券投资基金 基金份额发售公告。 公告称，华宝医药精选混合的募集已获中国证券监督管理委员会《关于准予华宝医药精选混合型证券投资基金注册的批复》准予注册。 该基金将自2026年8月10日起至2026年8月21日，通过基金管理人指定的销售机构公开发售。 该基金拟任基金经理为张金涛、杨洋。2021年4月加入华宝基金管理有限公司。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202607/29/20260729611833.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202607/29/20260729611833.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260729/32320687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09939","BK1515","159938","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655850881","title":"新济医药冲击IPO，报告期内累计亏损4.55亿元，家族色彩浓厚","url":"https://stock-news.laohu8.com/highlight/detail?id=2655850881","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655850881?lang=zh_cn&edition=full","pubTime":"2026-07-29 16:17","pubTimestamp":1785313051,"startTime":"0","endTime":"0","summary":"改良型新药","market":"hk","thumbnail":"https://img2.gelonghui.com/6475f-69474f9e-29c7-4e98-8fce-04b752eb96dc.jpg?guru_height=906&guru_width=1362&guru_size=182799","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/6475f-69474f9e-29c7-4e98-8fce-04b752eb96dc.jpg?guru_height=906&guru_width=1362&guru_size=182799"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5801987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","BK4127","159938","09939","FRHC","KCE","BK1574","REDS","IPOS","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785692333818,"stockEarnings":[{"period":"1week","weight":0.0287},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0047},{"period":"6month","weight":-0.0227},{"period":"1year","weight":-0.0915},{"period":"ytd","weight":-0.0062}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":-0.0681},{"period":"3month","weight":-0.0681},{"period":"6month","weight":-0.0694},{"period":"1year","weight":0.0725},{"period":"ytd","weight":-0.0344}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}